Even the shAXL knockdown with vehicle group had comparable leukemia burden and survival to the control group treated with 15 mg·kg−1 of gilteritinib, suggesting that AXL knockdown alone reduces leukemic progression (Fig. 7C,D). The gene discussed is AXL; the disease is leukemia.